Содержание
- 2. Patients with hematological malignancies in Belarus (adults) (2007).
- 3. Limphoproliferative diseases
- 4. B-cell lymphopoiesis
- 5. B-cell malignan-cies
- 6. T-cell differen-tiation stages
- 7. Lymphopoiesis in lymph nodes.
- 8. B-cell malignancies
- 9. Morphology of leukocytes
- 10. Acute leukemia. Originated from bone marrow (>25% blasts). Usually monoclonal disease. Lineage committed morphology (FAB classif.)
- 11. Acute leukemia (WHO classification, 2008). Mixed phenotype acute leukemia (T or B- myeloid, NK-cell…) B lymphoblastic
- 12. Cytogenetic and genetic features of ALL.
- 13. Chronic lymphocytic leukemia (WHO classification, 2008). Mature B-cell neoplasms Chronic lymphocytic leukemia/small lymphocytic lymphoma, B-cell prolymphocytic
- 14. Chronic lymphocytic leukemia (WHO classification, 2008). Mature T-cell and NK-cell neoplasms: T-cell prolymphocytic leukemia, T-cell large
- 15. Adverse prognostic factors of CLL Diffuse infiltration of bone marrow by lymphocytes; Advanced age; Male gender;
- 16. Typical B cell phenotype in CLL
- 17. Strategy for CLL therapy. First line of therapy: Fludarabine, Cyclophosphamine, Rituximabe (FCR). Chemotherapy, MABs such as
- 18. Types of lymphomas.
- 19. Hodgkin Lymphoma et al. (WHO, 2008). Hodgkin lymphoma: - classical Hodgkin lymphoma, - Lymphocyte-rich classical Hodgkin
- 20. Histological diagnosis of HD. The Reed–Sternberg cells are identified as large often bi-nucleated cells with prominent
- 21. The adverse prognostic factors for HD Age ≥ 45 years Stage IV disease Hemoglobin Lymphocyte count
- 22. Stages and Therapy of HD Therapy strategy: radiation therapy +/- chemotherapy. Prognosis: The 5-year survival rate
- 23. Non-Hodgkin lymphoma Causes The many different forms of lymphoma likely have different causes. These possible causes
- 26. Cytogenetic analysis for B-cell malignancies t(11;14) is mainly found in mantle cell lymphoma, but also in
- 27. Diagnosis of DLBCL by MicroArray technique: Germinal center B cell DLBCL vs activated (post-germinal center) B
- 28. Burkitt’s lymphoma (rare type of NHL) (endemic= EBV positive)
- 29. Immunophenotypic diagnosis of Burkitt’s lymphoma The cells of BL typically express monotypic surface IgM, CD19, CD20,
- 30. T (8,14) in Burkitt’s lymphoma
- 31. Path from Normal plasma cells through Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.
- 32. Plasma cell malignancies
- 33. Morphology of malignant plasma cells in blood (H&E staining)
- 34. Immunophenotyping of Plasma Cells
- 36. Multiple Myeloma diagnosis and therapy. Diagnosis: Roentgen + BM biopsy+.. Therapy: chemotherapy, BMT. Survival: 5-8 years.
- 37. Serum paraprotein detection
- 38. M-protein and diseases. More than 50% of patients with serum M protein have an initial clinical
- 39. Waldenstrom macroglobulinemia: pathogenesis Immunophenotype of BM cells in WM Ig light chain - Positive CD19 -
- 40. Diagnosis and Therapy of WM.
- 41. Light chain Disease (Bence-Jones proteins). A Bence Jones protein is a monoclonal globulion protein or immunoglobulin
- 42. (Bence-Jones protein in serum/urine (up) and serum (down))
- 43. HEAVY CHAIN DISEASE Heavy chain disease is a form of paraproteinemia with a proliferation of cells
- 45. Скачать презентацию